Cytogen Pharmaceuticals (India) Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 02-01-2025
- Paid Up Capital ₹ 1.60 M
as on 02-01-2025
- Company Age 21 Year, 1 Month
- Last Filing with ROC 31 Mar 2022
- Revenue -16.34%
(FY 2022)
- Profit 102.71%
(FY 2022)
- Ebitda 99.44%
(FY 2022)
- Net Worth 148.26%
(FY 2022)
- Total Assets 4.18%
(FY 2022)
About Cytogen Pharmaceuticals (India)
The Corporate was formerly known as Cytogen Pharmacuticals (India) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 1.60 M, as per Ministry of Corporate Affairs (MCA) records.
Venkatasatyasiva Bhupathiraju, Jhansirani Nadimpalli, and Jayapal Garapati serve as directors at the Company.
- CIN/LLPIN
U24239DL2003PTC123455
- Company No.
123455
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Dec 2003
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Cytogen Pharmaceuticals (India) Private Limited offer?
Cytogen Pharmaceuticals (India) Private Limited offers a wide range of products and services, including Common Disease Medicines, Pharmaceutical Medicine, Protein Supplements, Amino Acids.
Who are the key members and board of directors at Cytogen Pharmaceuticals (India)?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkatasatyasiva Bhupathiraju  | Director | 26-Oct-2020 | Current |
| Jhansirani Nadimpalli | Director | 26-Oct-2020 | Current |
| Jayapal Garapati | Whole-Time Director | 12-Nov-2020 | Current |
Financial Performance of Cytogen Pharmaceuticals (India).
Cytogen Pharmaceuticals (India) Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 16.34% decrease. The company also saw a substantial improvement in profitability, with a 102.71% increase in profit. The company's net worth Soared by an impressive increase of 148.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cytogen Pharmaceuticals (India)?
In 2022, Cytogen Pharmaceuticals (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Neovation Life Sciences India Private LimitedActive 5 years 6 months
Jhansirani Nadimpalli is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Cytogen Pharmaceuticals (India)?
Unlock and access historical data on people associated with Cytogen Pharmaceuticals (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cytogen Pharmaceuticals (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cytogen Pharmaceuticals (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
